Home | About us | Editorial Board | Search | Ahead of print | Current Issue | Archives | Instructions | Online submissionContact Us   |  Subscribe   |  Advertise   |  Login  Page layout
Wide layoutNarrow layoutFull screen layout
Lung India Official publication of Indian Chest Society  
  Users Online: 417   Home Print this page  Email this page Small font size Default font size Increase font size


 
  Table of Contents    
LETTER TO EDITOR
Year : 2018  |  Volume : 35  |  Issue : 6  |  Page : 540-541  

Asthma-chronic obstructive pulmonary disease overlap syndrome: Is prediction feasible?


1 Department of Anaesthesiology and Critical Care, All India Institute of Medical Sciences, Raipur, Chhattisgarh, India
2 Intensive Care Unit, Hospital Morales Meseguer, Murcia, Spain

Date of Web Publication30-Oct-2018

Correspondence Address:
Dr. Habi Md Reazaul Karim
Department of Anaesthesiology and Critical Care, All India Institute of Medical Sciences, Raipur, Chhattisgarh
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/lungindia.lungindia_142_18

Rights and Permissions

How to cite this article:
Karim HM, Esquinas AM. Asthma-chronic obstructive pulmonary disease overlap syndrome: Is prediction feasible?. Lung India 2018;35:540-1

How to cite this URL:
Karim HM, Esquinas AM. Asthma-chronic obstructive pulmonary disease overlap syndrome: Is prediction feasible?. Lung India [serial online] 2018 [cited 2018 Dec 16];35:540-1. Available from: http://www.lungindia.com/text.asp?2018/35/6/540/244490



Sir,

We read the article on predictors of asthma-chronic obstructive pulmonary disease overlap syndrome (ACOS) in your journal with great interest.[1] ACOS is indeed a clinically important subset of chronic respiratory disease patient population and has been given a position as one of four classes of chronic obstructive pulmonary disease (COPD) by the Spanish COPD guidelines.[2] For better recognition of this overlap syndrome, a diagnostic criterion was also set which requires fulfillment of two major and two minor criteria.[3]

However, we consider that some key aspects need to take into account for a proper clinical extrapolation. First, in the mentioned article, the authors have tried to find the predictors of overlap syndrome. However, it appears that they have given importance to a change in postbronchodilator forced expiratory volume in 1 s (FEV1) or forced vital capacity (FVC) by 12% and 200 ml as diagnostic criteria for ACOS in patients with postbronchodilator FEV1/FVC <70%, which is actually one of the minor criteria.[1],[3] We feel they should have used more than one parameter in criteria. Moreover, clinically significant bronchodilator response (≥15%) can be elicited in the majority of COPD patients too.[4] Therefore, using 12% and 200 ml as the only cutoff value reduces the reliability and specificities of the predictors they mentioned.

Second, while we were going through Table 1, we also found some confusing data in context to range of percentage reversibility and volume reversibility. Table 1 under the column of non-ACOS shows a range from minus to plus value which means that after bronchodilator the condition of some patients worsened, which is very unlikely, misleading, and probably impossible.

Third, we were unable to find the name of the software they have used for analysis. However, when we analyzed few data mentioned by the authors in their Table 2 using INSTAT software (GraphPad Prism Software Inc., La Jolla, USA) and used both Pearson's Chi-square test with Yate's continuity correction and Fisher's exact test with two-tailed P value (in 2 × 2 contingency table), it was found thatthe P values mentioned were either not reproducible or incorrect. As for example - the number of ER visits - P mentioned in the Table 2 is 0.04, but it came as 0.757 (Chi-square) and 0.684 (Fisher's exact test); ankle edema P mentioned <0.05 but it came as 0.705 (Chi-square) and 0.67 (Fisher's exact test) and so on. This is important with context to the point that both these features come out to be insignificant while the authors have mentioned them as significant predictors in conclusion. Further, clinical trials need to confirm these results.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
   References Top

1.
Ayub II, Arshad AM, Sekar P, Manimaran N, Thangaswamy D, Chockalingam C, et al. Predictors of asthma-chronic obstructive pulmonary disease overlap syndrome in patients with chronic obstructive pulmonary disease from a tertiary care center in India. Lung India 2018;35:137-42.  Back to cited text no. 1
[PUBMED]  [Full text]  
2.
Miravitlles M, Soler-Cataluña JJ, Calle M, Molina J, Almagro P, Quintano JA, et al. Spanish COPD guidelines (GesEPOC): Pharmacological treatment of stable COPD. Aten Primaria 2012;44:425-37.  Back to cited text no. 2
    
3.
Soler-Cataluña JJ, Cosío B, Izquierdo JL, López-Campos JL, Marín JM, Agüero R, et al. Consensus document on the overlap phenotype COPD-asthma in COPD. Arch Bronconeumol 2012;48:331-7.  Back to cited text no. 3
    
4.
Tashkin DP, Celli B, Decramer M, Liu D, Burkhart D, Cassino C, et al. Bronchodilator responsiveness in patients with COPD. Eur Respir J 2008;31:742-50.  Back to cited text no. 4
    




 

Top
  
 
  Search
 
  
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
    References

 Article Access Statistics
    Viewed187    
    Printed0    
    Emailed0    
    PDF Downloaded51    
    Comments [Add]    

Recommend this journal